Cefepime–taniborbactam activity against antimicrobial-resistant clinical isolates of Enterobacterales and Pseudomonas aeruginosa: GEARS global surveillance programme 2018–22 

Taniborbactam, a boronate-based β-lactamase inhibitor, was tested in combination with cefepime against Enterobacterales and Pseudomonas aeruginosa. The study found that taniborbactam reduced the cefepime MIC90 value for all Enterobacterales from >16 to 0.25 mg/L, inhibiting 99.5% of all Enterobacterales isolates and preventing 80% of isolates with meropenem-resistant and difficult-to-treat-resistant phenotypes. Against P. aeruginosa, taniborbactam reduced the cefepime MIC90 value from 32 to 8 mg/L, inhibiting 96.5% of all P. aeruginosa isolates. Multiple potential mechanisms of resistance were present in most isolates with cefepime–taniborbactam MICs≥ 16 mg/L. The study concluded that cefepime–taniborbactam exhibited potent in vitro activity against Enterobacterales and P. aeruginosa, and inhibited most carbapenem-resistant isolates, including those carrying serine carbapenemases or NDM/VIM MBLs.